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Abstract
Background: In a substantial proportion of respiratory tract diseases of suspected infectious
origin, the etiology is unknown. Some of these cases may be caused by the recently described
human bocavirus (hBoV). The aim of this study was to investigate the frequency and the potential
clinical relevance of hBoV in pediatric patients.
Methods: We tested 835 nasopharyngeal aspirates (NPA) obtained between 2002 and 2005 from
pediatric in-patients with acute respiratory tract diseases at the University of Würzburg, Germany,
for the presence of hBoV DNA. The specificity of positive PCR reactions was confirmed by
sequencing.
Results: HBoV DNA was found in 87 (10.3 %) of the NPAs. The median age of the infants and
children with hBoV infection was 1.8 years (mean age 2.0 years; range 18 days – 8 years). Infections
with hBoV were found year-round, though most occurred in the winter months. Coinfections were
found in 34 (39.1 %) of the hBoV positive samples. RSV, influenza A, and adenoviruses were most
frequently detected as coinfecting agents. Sequence determination of the PCR products in the NP-
1 region revealed high identity (99 %) between the nucleotide sequences obtained in different years
and in comparison to the Swedish viruses ST1 and ST2. An association of hBoV with a distinct
respiratory tract manifestation was not apparent.
Conclusion: HBoV is frequently found in NPAs of hospitalized infants and children with acute
respiratory tract diseases. Proving the clinical relevance of hBoV is challenging, because application
of some of Koch's revised postulates is not possible. Because of the high rate of coinfections with
hBoV and other respiratory tract pathogens, an association between hBoV and respiratory tract
diseases remains unproven.
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Background
Respiratory tract infections are a major cause of human
morbidity and are caused by a broad spectrum of micro-
bial agents. Viruses account for the largest number of res-
piratory tract infections. The so-called respiratory viruses
include influenza virus A and B, parainfluenzae viruses,
adenoviruses, respiratory syncytial virus (RSV), rhinovi-
ruses, and coronaviruses. In recent years, several novel
viruses have been discovered in patients with respiratory
infections using molecular biology methods. These novel
viruses include the human metapneumovirus and several
coronaviruses (SARS, NL63, HKU1) [1,2]. The latest addi-
tion to this list was the human bocavirus (hBoV)
described by Allander et al. [3]. Their screening method
for unknown viral sequences in patient samples involved
concentration of viral particles, nucleic acid isolation, ran-
dom amplification of RNA and DNA, and finally sequenc-
ing and subsequent blasting of the amplified products.
HBoV is most closely related to the minute virus of
canines (MVC) and the Bovine Parvovirus (BPV), which
have been classified in the genus Bocavirus within the Par-
voviridae [4].
Classically, the postulates of Koch as modified by Rivers
have been used to establish a causal relationship between
viruses and a disease [5]. However, hBoV has not been
propagated in cell culture, and there is no animal model
so far. Therefore, proving the clinical relevance is chal-
lenging because application of some postulates of Koch
and Rivers is not possible.
In the first description of hBoV, DNA was detected in 17
(3.1 %) of 540 Swedish children with lower respiratory
tract disease. Three of the children were coinfected with
other viruses (two with RSV and one with adenovirus).
Because 14 hBoV-positive samples were negative for other
respiratory viruses by standard screening, it was reasoned
that hBoV may cause respiratory tract disease. In a second
report of hBoV in Australian children and adults, hBoV
was detected in 18 (5.6 %) of 324 respiratory samples. In
ten of these (55.6 %), a coinfection with RSV (n = 8),
hMPV or adenoviruses was detected [6]. In a third study
from Japan, hBoV DNA was found in 18 (5.7 %) of 318
respiratory specimens of children with lower respiratory
tract disease [7]. Samples positive for other viruses (RSV,
influenza virus A and B, hMPV) were excluded from the
study. Analysis of double infections was therefore not pos-
sible. In two more recent studies from Canada and France,
hBoV DNA was detected in 18 of 1209 (1.5 %) and nine
of 262 (3.4 %) respiratory samples, respectively [8,9]. In
the Canadian study specimens of children and adults were
tested. Specimens positive for other respiratory viruses
were excluded. The French study examined samples of
children below five years of age. Three of the nine hBoV
DNA positive children (33.3 %) were coinfected with RSV.
In order to better understand the epidemiological pattern
of hBoV infections and to analyze its clinical relevance,
further studies on larger groups of patients are necessary.
Therefore, we retrospectively tested nasopharyngeal aspi-
rates of patients from the University of Würzburg Chil-
dren's Hospital, Germany for the presence of hBoV DNA.
Methods
Samples
The samples tested for hBoV infection consisted of stored
nasopharyngeal aspirates (NPA) that were sent by the
University of Würzburg Children's hospital for screening
of respiratory viruses from January 2002 to September
2005. On arrival in the viral diagnostic laboratory, the
samples were routinely tested for the presence of respira-
tory virus antigens with an immunofluorescence assay
(Respiratory Panel IFA Kit, Chemicon). The screening rea-
gent of the kit detects antigens of adenoviruses, influenza
viruses A and B, parainfluenza viruses 1 – 3, and RSV.
NPAs showing positive reactions with the screening rea-
gent were further studied by IFA using the seven single
monoclonal antibodies contained in the screening rea-
gent. Remaining NPA material was stored at -20°C until
further testing for hBoV DNA. In addition to the samples
from 2002 – 2005, a small number of samples (n = 17)
from 1997 – 2001 were also available for retrospective
testing. The study was carried out in compliance with the
Helsinki declaration and was approved by the ethics com-
mittee of the medical faculty at the University of Würz-
burg.
hBoV PCR and sequencing
DNA was extracted from 200 μl of the NPA samples using
the High Pure Viral Nucleic Acid Kit (Roche, Mannheim,
Germany) according to the instructions of the manufac-
turer. The elution volume was 50 μl. Amplification of
hBoV DNA was performed with the NP-1 primers
BoV188F (GAGCTCTGTAAGTACTATTAC) and BoV542R
(CTCTGTGTTGACTGAATACAG) described by Allander
[3] using the HotStarTaq DNA Polymerase (Qiagen,
Hilden, Germany). PCR reactions were carried out in a 50
μl volume consisting of 5 μl extracted DNA, 1× Qiagen
HotStar buffer, dNTPs at a final concentration of 200 μM
each, 200 pmol of each primer, and 1.5 U of Taq Polymer-
ase. The cycling conditions were 50 cycles (94°C 30 s,
53°C 40 s and 1 min at 72°C) after a preheating step of
10 min at 95°C.
After amplification, PCR products were visualized by
staining with ethidium bromide on agarose gels. A PCR
reaction was considered as positive when a band of the
expected size (354 base pairs) was visible. To confirm the
sequence specificity, all PCR products from positive reac-
tions were sequenced completely in both directions usingBMC Infectious Diseases 2006, 6:109 http://www.biomedcentral.com/1471-2334/6/109
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Big Dye terminator chemistry and the ABI Prism 3100
(Applied Biosystems, Darmstadt, Germany).
General laboratory procedures to prevent PCR contamina-
tion were strictly adhered to. One negative control was
extracted and amplified for every five NPA samples. All
negative controls were found to be negative for hBoV
DNA. A plasmid containing the PCR product cloned in
the vector pCR®2.1-TOPO® (Invitrogen) was used as posi-
tive control. The sensitivity of the hBoV assay was approx-
imately 10 copies per reaction.
Results
From January 2002 to September 2005, 901 nasopharyn-
geal aspirates (NPA) of 786 hospitalized infants and chil-
dren with febrile respiratory tract diseases were received
for viral diagnostic evaluation. The median age of the
patients was 1.6 years (mean age 3.4 years; range 12 days
– 16 years), and 59 % were boys. The seasonal distribu-
tion of all samples is shown in Figure 1. Because of insuf-
ficient volume of the stored material, 66 samples had to
be excluded from the retrospective testing of hBoV DNA.
The median age and the seasonal distribution of the hos-
pitalization were not significantly different between the
patients with and without sufficient NPA sample volume.
By routine immunofluorescence testing for antigen of res-
piratory viruses, a positive diagnosis was obtained for 357
(39.5 %) of the NPA samples. RSV (n = 158; 17.4 %) and
influenza A virus (n = 98; 10.9 %) were most frequently
found. Further details are shown in Table 1. Coinfections
with two or more viruses were detected in 7 of the cases
using the antigen assay.
Of the 835 NPAs tested for hBoV DNA, 87 (10.3%) sam-
ples were found to be positive by PCR and subsequent
sequencing. The male to female ratio of the hBoV positive
infants and children (59.8 % boys) was similar to the ratio
in the population tested. Their median age was 1.8 years
(mean 2.0 years; range 18 days – 8 years). The age distri-
bution of the hBoV positive patients and of the RSV, ade-
novirus and influenza A virus positive children for
comparison is shown in Figure 2. Median ages were signif-
icantly different for these four infectious agents, except for
the comparison between influenza A and adenovirus
infections (Table 2). While infections with RSV peaked
during the first six months of life (median 0.7 years), most
hBoV infections (n = 52; 59.8 %) occurred at the age of 1
– 3 years. Infections with influenza A virus were more
evenly distributed over a wider age range (median 2.7
years).
Infections with hBoV were found year-round, though
most occurred in the winter months (Figure 1). The shape
of the curves of the total number of NPA samples received
and of the hBoV positive samples appeared to be almost
in parallel. There were no significant differences between
the yearly frequencies of hBoV positive results between
2002 and 2005 (Table 3). In 17 samples that were availa-
ble from before 2002, HBoV was retrospectively found in
3 samples, two from 1998 and one from 2001.
In 34 (39.1 %) of the hBoV positive infants and children,
coinfections with other respiratory viruses were present,
most frequently with RSV (n = 14) followed by influenza
A (n = 9). The percentage distribution of the coinfecting
agents among the hBoV positive samples was similar to
the distribution of these agents in the total population
(Table 1).
Sequence determination of the hBoV PCR products (NP-1
region of the genome) revealed high identity (99 %)
between the nucleotide sequences obtained in different
years and in comparison to the Swedish viruses ST1 and
ST2.
Clinical data were available for 63 of the 87 hBoV positive
NPAs. The patients suffered from upper and/or lower res-
piratory tract diseases (Table 4). Associations between all
hBoV infections and distinct clinical manifestations were
not apparent. Because of the retrospective nature of the
study and because clinical data for the hBoV negative sam-
ples were not obtained, a statistical analysis of this aspect
was not possible. When the clinical diagnoses of the chil-
dren with and without coinfections with other respiratory
pathogens were compared, pneumonia was found more
often in the group of children without coinfections (Table
4). This association was borderline significant (p = 0.044
by Fisher's exact test).
Discussion
We found hBoV DNA in 10.3 % of NPA samples obtained
from infants and children with respiratory tract diseases
during the years 2002 to 2005 in the region of northern
Bavaria in Germany. This is the highest frequency
reported so far. To our knowledge, there have been five
previous reports on hBoV infections, the original report
from Sweden with a frequency of 3.1 %, and reports from
Australia, Japan, Canada and France with frequencies of
5.6 %, 5.7 %, 1.5 %, and 3.4 %, respectively. In our study,
hBoV infections were almost as frequently found as infec-
tions with influenza A virus, the second most common
respiratory infection, and they were considerably more
frequent than infections with influenza B, parainfluenzae,
and adenoviruses. However, in contrast to the PCR
method used for hBoV detection, the other respiratory
viruses in our study were examined by IFA. When compar-
ing the detection frequencies, this difference in detection
methods has to be taken into consideration. In general,
PCR assays are more sensitive than antigen detectionBMC Infectious Diseases 2006, 6:109 http://www.biomedcentral.com/1471-2334/6/109
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Temporal distribution of hBoV infections Figure 1
Temporal distribution of hBoV infections. Temporal distribution of the hBoV DNA positive NPAs compared with the 
total number of NPAs received and with the total number of positive results by immunofluorescence staining for antigen of 
respiratory viruses (RSV, influenza A/B, parainfluenza 1/2/3, adenoviruses).
Table 1: Frequency of detection of respiratory viruses and of hBoV in NPA samples
Total population n Positive results n Males
Results of IFA testing for viral 
antigen
901 59.0 %
Total positive results by IFA 901 357 (39.5 %) 55.5 %
• RSV 901 158 (17.4 %) 52.5 %
• Influenza A 901 98 (10.9 %) 57.1 %
• Adenovirus 901 53 (5.9 %) 62.3 %
• Parainfluenza 1/2/3 901 39 (4.3 %) 48.7 %
• Influenza B 901 16 (1.8 %) 50.0 %
• Coinfections 901 7 (0.8 %) 14.3 %
Results of hBoV PCR 835 87 (10.3 %) 59.8 %
hBoV positive with coinfections 87 34 (39.1 %) 58.8 %
• with RSV 87 14 (16.1 %)
• with influenza A 87 9 (10.3 %)
• with adenovirus 87 9 (10.3 %)
• with parainfluenza 1/2/3 87 1 (1.1 %)
• with influenza B 87 1 (1.1 %)BMC Infectious Diseases 2006, 6:109 http://www.biomedcentral.com/1471-2334/6/109
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methods [10]. Therefore, it is likely that the true preva-
lence of the respiratory viruses that were analyzed by IFA
is actually higher than here reported.
There are several possible explanations for the higher fre-
quency of hBoV infections observed in our study com-
pared to the previous reports. Firstly, the difference may
be due to an increased sensitivity of our PCR assay. In all
previous studies as well as in ours, single round hot-start
PCRs have been employed to detect hBoV DNA. However,
the assays vary in the number of PCR cycles performed (35
cycles [3,7-9]; 45 cycles [6]; 50 cycles (present study)).
Depending on the assay optimization, 35 cycles may not
be sufficient to detect weakly positive samples. In addi-
tion, data on the assay sensitivity were not provided in
either of the previous studies. Using a plasmid control, we
were able to show that our assay regularly detects approx-
imately 10 copies of hBoV DNA per reaction. In order to
obtain information on the amount of hBoV DNA present
in the NPAs and in other secretions, a real-time PCR assay
is currently under development.
A second potential reason for differing infection frequen-
cies between studies may be due to regional and temporal
Table 2: Median age of patients with viral respiratory tract infections
p-values1 for groupwise comparison
Infection with n Median age RSV Adeno Influenza A
hBoV 87 1.8 p < 0.0001 p = 0.0046 p = 0.0031
RSV 158 0.7 p < 0.0001 p < 0.0001
Adenovirus 53 2.7 p = 0.8
Influenzavirus A 98 2.4
1by Mann-Whitney-test
Age distribution of hBoV infections Figure 2
Age distribution of hBoV infections. Age distribution of hBoV infected children compared with the age distribution of chil-
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differences in the incidence of hBoV infection. In contrast
to the previous reports, which have studied samples from
only one or two winter seasons, the NPAs in our studies
have been collected during four consecutive years. In gen-
eral, seasonal differences of sample acquisition may
account for varying incidence numbers. In our study, for
example, proportions of influenza A, parainfluenza 3, and
adenovirus infections were considerably different
between winter seasons (data not shown). However, this
was not the case for hBoV infections. In four consecutive
winter seasons, we observed a similar frequency of
approximately 10 %. Therefore, seasonal variation is
unlikely to account for the observed high frequency of
hBoV infections in our study population. So far, hBoV has
been detected in Sweden, Australia, Japan, Canada,
France, and Germany, and it appears that hBoV has a
worldwide distribution. It remains to be determined how
incidence numbers are influenced by regional aspects.
Thirdly, the higher frequency observed in our study may
be related to different patient populations. Children hos-
pitalized for respiratory tract diseases were included in all
studies published so far [3,6-9]. Two studies additionally
examined adults and outpatients [6,8]. While three stud-
ies as well as ours included patients with upper and/or
lower respiratory tract disease [6,8,9], two studies focused
on patients with lower respiratory tract diseases [3,7].
Thus, it is difficult to compare patient populations in the
hBoV studies.
In agreement with the previous reports [3,6-9], sequenc-
ing of the PCR products in the NP-1 region revealed a
nucleotide identity of more than 99 % between different
samples. This was also true for the two hBoV DNA positive
samples from 1998. Although much more sequence infor-
mation on hBoV will be required, the data available so far
indicate that hBoV may be a highly conserved virus.
The age distribution of hBoV infections found in our
study is similar to previous reports [3,6-9]. Most hBoV
infections occurred between 6 months and 3 years of age.
This distribution is compatible with protection from
infection by maternal antibodies in the first year of life.
Future studies of the seroprevalence of hBoV antibodies in
different age groups will shed light on this issue.
Analysis of a potential association between hBoV infec-
tion and clinical manifestations is limited by the retro-
spective nature of our study, by the high number of
double infections, and by the fact that clinical informa-
tion was obtained only for hBoV positive patients. How-
ever, it seems that there is no obvious association between
hBoV infection and a distinct clinical manifestation.
Instead, a broad spectrum of both upper and lower respi-
Table 4: Clinical manifestations in 63 hBoV DNA positive infants and children with and without coinfections1
Diagnosis at discharge from hospital n with coinfection n without coinfection total n (%)
Upper respiratory tract disease (rhinitis, otitis media, tonsillitis, pharyngitis, 
laryngotracheitis, apnoic spells)
12 13 25 (39.7 %)
Lower respiratory tract disease (total) 8 24 32 (50.8 %)
• bronchitis 3 7 10 (15.9 %)
• wheezing bronchitis 4 5 9 (14.3 %)
• bronchiolitis 02 2  ( 3 . 2  % )
• pneumonia 11 0 2 11 (17.5 %)
Febrile seizures 33 6  ( 9 . 5  % )
1Clinical information was available for 63 of the 87 hBoV DNA positive samples
2p = 0.044 by Fisher's exact test
Table 3: Seasonal frequency of hBoV infections
Period1 NPA samples tested n hBoV positive NPAs n (%)
Jan 02 – June 02 59 7 (11.9%)
July 02 – June 03 159 19 (11.9%)
July 03 – June 04 169 19 (11.2%)
July 04 – June 05 405 36 (8.9%)
July 05 – Sep 05 43 6 (14.0%)
1Observation periods were chosen from summer to summer whenever possible in order to include the complete winter seasonBMC Infectious Diseases 2006, 6:109 http://www.biomedcentral.com/1471-2334/6/109
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ratory tract diseases was observed. When clinical diag-
noses of hBoV DNA positive patients with and without
coinfections were compared, pneumonia was found more
frequently in children without coinfection. However, this
association of borderline significance (p = 0.044) should
be regarded with caution because of small numbers. If
pneumonia was caused by hBoV infection, it is unclear
how a coinfection could result in a less frequent manifes-
tation of this disease.
The assumption in the first description of hBoV, that this
virus might be an etiologic agent of respiratory tract dis-
ease, was based on the fact that hBoV infections were
found significantly more often in samples negative for
other respiratory viruses. However, with coinfection rates
ranging fom 33.3 % to 55.6 %, these findings were neither
confirmed by the other studies that analyzed coinfections
[6] nor by us. The true number of coinfections in our
study is probably even higher than the reported 39.1 %,
because antigen-based methods were used for screening of
respiratory viruses other than hBoV, and because several
respiratory pathogens such as coronaviruses, rhinoviruses,
enteroviruses and the human metapneumovirus were not
tested for. On the basis of the considerable number of
coinfections, one might argue that hBoV is an aggravating
factor of respiratory diseases, an innocent bystander that
is just detected by chance, or a persisting virus that is reac-
tivated by the inflammatory process.
Thus, it is uncertain at present, if hBoV is indeed an etio-
logic agent of respiratory tract (or other) diseases. Several
viruses detected by molecular biology methods in recent
years are still in search for a relevant clinical disease
[11,12]. If hBoV has to be added to this list remains to be
determined.
Conclusion
HBoV is frequently found in NPAs of hospitalized chil-
dren with acute respiratory tract diseases. Proving the clin-
ical relevance of hBoV is challenging, because application
of some postulates of Koch is not possible. Because of the
high rate of coinfections with hBoV and other respiratory
pathogens, an association between hBoV and respiratory
tract diseases remains unproven.
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